The role of different VEGF isoforms in scar formation after glaucoma filtration surgery

Experimental Eye Research

Volumn 93, Issue 5, 2011, Pages 689-699

  Van Bergen, Tine ^a   Vandewalle, Evelien ^a,b   Van de Veire, Sara ^a,b   Dewerchin, Mieke ^a   Stassen, Jean Marie ^c   Moons, Lieve ^a   Stalmans, Ingeborg ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ThromboGenics NV   (Belgium)

Author keywords

Glaucoma filtration surgery; Human umbilical vein endothelial cells; Pegaptanib; Tenon fibroblasts; Vascular endothelial growth factor; Wound healing

Indexed keywords

BEVACIZUMAB; NEUROPILIN 1; PEGAPTANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 189; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FIBROBLAST; FIBROSIS; GLAUCOMA; GLAUCOMA FILTRATION SURGERY; GLAUCOMA SURGERY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MORPHOMETRICS; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; SCAR FORMATION; SURVIVAL; TRABECULECTOMY; TREATMENT OUTCOME; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLASTS; FIBROSIS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MAP KINASE SIGNALING SYSTEM; NEUROPILIN-1; PROTEIN ISOFORMS; RABBITS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TENON CAPSULE; TRABECULAR MESHWORK; TRABECULECTOMY; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WOUND HEALING;

EID: 81355146486     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.08.016     Document Type: Article

References (60)

1. Addicks E.M., Quigley H.A., Green W.R., Robin A.L. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch. Ophthalmol. 1983, 101:795-798.
2. Akiyama M., Yamada O., Hideshima T., Yanagisawa T., Yokoi K., Fujisawa K., Eto Y., Yamada H., Anderson K.C. TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes. Biochem. Biophys. Res. Commun. 2004, 316:528-532.
3. Apte R.S., Modi M., Masonson H., Patel M., Whitfield L., Adamis A.P. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007, 114:1702-1712.
4. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Singh R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007, 114:855-859.
5. Beddy D., Watson R.W., Fitzpatrick J.M., O'Connell P.R. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br. J. Surg. 2004, 91:72-77.
6. Brusselmans K., Bono F., Collen D., Herbert J.M., Carmeliet P., Dewerchin M. A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J. Biol. Chem. 2005, 280:3493-3499.
7. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
8. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
9. Castro-Rivera E., Ran S., Thorpe P., Minna J.D. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11432-11437.
10. Chao S.C., Hu D.N., Yang P.Y., Lin C.Y., Yang S.F. Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts. Mol. Vis. 2011, 17:23-31.
11. Ciulla T.A., Rosenfeld P.J. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 2009, 20:158-165.
12. Cordeiro M.F., Mead A., Ali R.R., Alexander R.A., Murray S., Chen C., York-Defalco C., Dean N.M., Schultz G.S., Khaw P.T. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 2003, 10:59-71.
13. Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., Blacher S., Verdin E., Foidart J.M., Nusgens B.V., Castronovo V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002, 21:427-436.
14. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237:97-132.
15. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
16. Gillies M.C., Su T. Cytokines, fibrosis and the failure of glaucoma filtration surgery. Aust. N. Z. J. Ophthalmol. 1991, 19:299-304.
17. Greenfield D.S., Liebmann J.M., Jee J., Ritch R. Late-onset bleb leaks after glaucoma filtering surgery. Arch. Ophthalmol. 1998, 116:443-447.
18. Haag M., Van Linthout S., Schroder S.E., Freymann U., Ringe J., Tschope C., Sittinger M. Endomyocardial biopsy derived adherent proliferating cells - a potential cell source for cardiac tissue engineering. J. Cell Biochem. 2010, 109:564-575.
19. Herve M.A., Buteau-Lozano H., Mourah S., Calvo F., Perrot-Applanat M. VEGF189 stimulates endothelial cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. Exp. Cell Res. 2005, 309:24-31.
20. Hitchings R.A., Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans. Ophthalmol. Soc. U. K. 1983, 103(Pt 1):84-88.
21. Ishida S., Usui T., Yamashiro K., Kaji Y., Ahmed E., Carrasquillo K.G., Amano S., Hida T., Oguchi Y., Adamis A.P. VEGF164 is proinflammatory in the diabetic retina. Invest. Ophthalmol. Vis. Sci. 2003, 44:2155-2162.
22. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Oguchi Y., Ambati J., Miller J.W., Gragoudas E.S., Ng Y.S., D'Amore P.A., Shima D.T., Adamis A.P. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 2003, 198:483-489.
23. Jampel H.D., McGuigan L.J., Dunkelberger G.R., L'Hernault N.L., Quigley H.A. Cellular proliferation after experimental glaucoma filtration surgery. Arch. Ophthalmol. 1988, 106:89-94.
24. Katz G.J., Higginbotham E.J., Lichter P.R., Skuta G.L., Musch D.C., Bergstrom T.J., Johnson A.T. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 1995, 102:1263-1269.
25. Khaw P., Grehn F., Hollo G., Overton B., Wilson R., Vogel R., Smith Z. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 2007, 114:1822-1830.
26. Khaw P.T., Doyle J.W., Sherwood M.B., Grierson I., Schultz G., McGorray S. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Arch. Ophthalmol. 1993, 111:263-267.
27. Kim W.U., Kang S.S., Yoo S.A., Hong K.H., Bae D.G., Lee M.S., Hong S.W., Chae C.B., Cho C.S. Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation. J. Immunol. 2006, 177:5727-5735.
28. Kokolakis G., Mikelis C., Papadimitriou E., Courty J., Karetsou E., Katsoris P. Effect of heparin affin regulatory peptide on the expression of vascular endothelial growth factor receptors in endothelial cells. In Vivo 2006, 20:629-635.
29. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 2006, 12:5018-5022.
30. Lama P.J., Fechtner R.D. Antifibrotics and wound healing in glaucoma surgery. Surv. Ophthalmol. 2003, 48:314-346.
31. Lee P.F., Myers K.S., Hsieh M.M., Wood E.F., Hotaling D.M. Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA). J. Ocul. Pharmacol. Ther. 1995, 11:227-232.
32. Li W.W., Li V.W. Therapeutic angiogenesis for wound healing. Wounds - A Compend. Clin. Res. Pract. 2003, 15:3S-12S.
33. Li Z., Van Bergen T., Van de Veire S., Van de Vel I., Moreau H., Dewerchin M., Maudgal P.C., Zeyen T., Spileers W., Moons L., Stalmans I. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci. 2009, 50:5217-5225.
34. Mead A.L., Wong T.T., Cordeiro M.F., Anderson I.K., Khaw P.T. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 2003, 44:3394-3401.
35. Memarzadeh F., Varma R., Lin L.T., Parikh J.G., Dustin L., Alcaraz A., Eliott D. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest. Ophthalmol. Vis. Sci. 2009, 50:3233-3237.
36. Murakami M., Iwai S., Hiratsuka S., Yamauchi M., Nakamura K., Iwakura Y., Shibuya M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 2006, 108:1849-1856.
37. Nissen N.N., Polverini P.J., Koch A.E., Volin M.V., Gamelli R.L., DiPietro L.A. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am. J. Pathol. 1998, 152:1445-1452.
38. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
39. Pap T., Nawrath M., Heinrich J., Bosse M., Baier A., Hummel K.M., Petrow P., Kuchen S., Michel B.A., Gay R.E., Muller-Ladner U., Moelling K., Gay S. Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum. 2004, 50:2794-2802.
40. Pintus G., Tadolini B., Posadino A.M., Sanna B., Debidda M., Bennardini F., Sava G., Ventura C. Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur. J. Biochem. 2002, 269:5861-5870.
41. Plouet J., Moro F., Bertagnolli S., Coldeboeuf N., Mazarguil H., Clamens S., Bayard F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J. Biol. Chem. 1997, 272:13390-13396.
42. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 2005, 23:1028-1043.
43. Roberts J.R., Perkins G.D., Fujisawa T., Pettigrew K.A., Gao F., Ahmed A., Thickett D.R. Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit. Care Med. 2007, 35:2164-2170.
44. Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 2001, 114:853-865.
45. Seth A., Gonzalez F.A., Gupta S., Raden D.L., Davis R.J. Signal transduction within the nucleus by mitogen-activated protein kinase. J. Biol. Chem. 1992, 267:24796-24804.
46. Skuta G.L., Parrish R.K. Wound healing in glaucoma filtering surgery. Surv. Ophthalmol. 1987, 32:149-170.
47. Soker S., Miao H.Q., Nomi M., Takashima S., Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell Biochem. 2002, 85:357-368.
48. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
49. Stalmans I., Lambrechts D., De Smet F., Jansen S., Wang J., Maity S., Kneer P., von der Ohe M., Swillen A., Maes C., Gewillig M., Molin D.G., Hellings P., Boetel T., Haardt M., Compernolle V., Dewerchin M., Plaisance S., Vlietinck R., Emanuel B., Gittenberger-de Groot A.C., Scambler P., Morrow B., Driscol D.A., Moons L., Esguerra C.V., Carmeliet G., Behn-Krappa A., Devriendt K., Collen D., Conway S.J., Carmeliet P. VEGF: a modifier of the del22q11 (DiGeorge) syndrome?. Nat. Med. 2003, 9:173-182.
50. Stalmans I., Ng Y.S., Rohan R., Fruttiger M., Bouche A., Yuce A., Fujisawa H., Hermans B., Shani M., Jansen S., Hicklin D., Anderson D.J., Gardiner T., Hammes H.P., Moons L., Dewerchin M., Collen D., Carmeliet P., D'Amore P.A. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 2002, 109:327-336.
51. Takahashi T., Yamaguchi S., Chida K., Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 2001, 20:2768-2778.
52. Tirand L., Frochot C., Vanderesse R., Thomas N., Trinquet E., Pinel S., Viriot M.L., Guillemin F., Barberi-Heyob M. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J. Control. Release 2006, 111:153-164.
53. Usui T., Ishida S., Yamashiro K., Kaji Y., Poulaki V., Moore J., Moore T., Amano S., Horikawa Y., Dartt D., Golding M., Shima D.T., Adamis A.P. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest. Ophthalmol. Vis. Sci. 2004, 45:368-374.
54. Wells A.P., Crowston J.G., Marks J., Kirwan J.F., Smith G., Clarke J.C., Shah R., Vieira J., Bunce C., Murdoch I., Khaw P.T. A pilot study of a system for grading of drainage blebs after glaucoma surgery. J. Glaucoma 2004, 13:454-460.
55. Wilgus T.A., Ferreira A.M., Oberyszyn T.M., Bergdall V.K., Dipietro L.A. Regulation of scar formation by vascular endothelial growth factor. Lab. Invest. 2008, 88:579-590.
56. Wu Y., Zhang Q., Ann D.K., Akhondzadeh A., Duong H.S., Messadi D.V., Le A.D. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am. J. Physiol. Cell Physiol. 2004, 286:C905-C912.
57. Yamazaki Y., Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol. Divers. 2006, 10:515-527.
58. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 2003, 31:1171-1177.
59. Zhang H.T., Scott P.A., Morbidelli L., Peak S., Moore J., Turley H., Harris A.L., Ziche M., Bicknell R. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br. J. Cancer 2000, 83:63-68.
60. Zhang Y., Furumura M., Morita E. Distinct signaling pathways confer different vascular responses to VEGF 121 and VEGF 165. Growth Factors 2008, 26:125-131.